| Literature DB >> 35090398 |
Pablo Vial1, Claudia González2, Gloria Icaza3, Muriel Ramirez-Santana4, Rubén Quezada-Gaete4, Loreto Núñez-Franz5, Mauricio Apablaza6, Cecilia Vial1, Paola Rubilar2, Juan Correa7, Claudia Pérez8, Andrei Florea1, Eugenio Guzmán6, María-Estela Lavín6, Paula Concha8, Manuel Nájera2, Ximena Aguilera9.
Abstract
BACKGROUND: Seroprevalence studies provide an accurate measure of SARS-CoV-2 spread and the presence of asymptomatic cases. They also provide information on the uneven impact of the pandemic, pointing out vulnerable groups to prioritize which is particularly relevant in unequal societies. However, due to their high cost, they provide limited evidence of spatial spread of the pandemic specially in unequal societies. Our objective was to estimate the prevalence of SARS-CoV-2 antibodies in Chile and model its spatial risk distribution.Entities:
Keywords: Attack rate; COVID-19; Case fatality ratio; Chile; Geography; Household transmission; Secondary attack rate; Seroprevalence; Spatial analysis
Mesh:
Year: 2022 PMID: 35090398 PMCID: PMC8795965 DOI: 10.1186/s12879-022-07045-7
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Flowchart participants in seroprevalence of SARS-CoV-2 antibodies study in three urban centers of Chile 2020
Fig. 2Geographical distribution of study sites and SARS-CoV-2 antibodies in three urban centers of Chile 2020
Population seroprevalence of SARS-CoV-2 and sociodemographic variables, Chile 2020
| Participants (n) | Seropositive (n) | Seroprevalencea % (95% CI) | OR (95% CI) | |
|---|---|---|---|---|
| Overall | 2493 | 242 | 10.4 (7.8–13.7) | – |
| City: | ||||
| -Coquimbo- La Serena | 478 | 30 | 5.6 (3.3–9.5) | 2.91 (1.01–8.44) |
| -Santiago | 1441 | 200 | 11.0 (8.2–14.7) | 6.1 (2.3–15.8) |
| -Talca | 574 | 12 | 2.0 (0.8–4.7) | Ref |
| Sex: | ||||
| -Male | 990 | 107 | 12.2 (8.3–17.5) | 1.5 (0.9–2.4) |
| -Female | 1503 | 135 | 8.7 (6.2–12.0) | Ref |
| Age Group: | ||||
| -7–14 | 176 | 21 | 12.5 (6.1–23.8) | Ref |
| -15–24 | 360 | 38 | 9.0 (5.2–15.3) | 0.70 (0.26–1.86) |
| -25–39 | 649 | 62 | 10.4 (6.5–16.2) | 0.81 (0.32–2.04) |
| -40–59 | 813 | 93 | 12.1 (7.8–18.3) | 0.97 (0.42–2.22) |
| -≥ 60 | 495 | 28 | 6.7 (3.4–12.9) | 0.50 (0.18–1.41) |
| Nationality: | ||||
| -Chilean | 2378 | 221 | 9.3 (7.1–12.1) | Ref |
| -Foreign | 115 | 21 | 21.6 (9.1–43.2) | 2.69 (0.96–7.56) |
| Native South American Ethnicity:b | ||||
| -Yes | 230 | 23 | 17.8 (7.0–38.6) | 2.0 (0.66–6.03) |
| -No | 2263 | 219 | 9.7 (7.3–13.0) | Ref |
| Educational level (for participants > 17 years old) (n = 2234): | ||||
| -None or primary | 234 | 11 | 4.3 (1.6–11.2) | 0.63 (0.19–2.09) |
| -Secondary | 1130 | 130 | 14.2 (10.0–19.8) | 2.30 (1.16–4.54) |
| -Technical | 330 | 38 | 9.5 (5.1–17.0) | 1.46 (0.59–3.57) |
| -University | 540 | 36 | 6.7 (3.7–11.9) | Ref |
| Health Insurance (n = 2347): | ||||
| -Public | 1811 | 192 | 12.7 (9.3–17.2) | 2.5 (1.25–5.10) |
| -Private | 536 | 44 | 5.5 (2.9–9.9) | Ref |
| Overcrowding (n = 2487): | ||||
| -No | 2338 | 219 | 10.7 (7.9–14.2) | Ref |
| -Yes | 149 | 23 | 7.5 (2.9–18.1) | 0.68 (0.24–1.96) |
| Number of residents: | ||||
| -< 5 | 1651 | 9.3 | 6.2–13.8 | Ref |
| -≥ 5 | 842 | 12.8 | 8.9–18.2 | 1.43 (0.79–2.62) |
| Type of dwelling (n = 2486): | ||||
| -House | 2142 | 201 | 10.3 (7.7–13.6) | Ref |
| -Apartment | 344 | 38 | 10.5 (6.1–17.5) | 1.02 (0.52–2.02) |
| Heating Fuel (2486) Gas: | ||||
| -No | 1315 | 120 | 9.4 (6.6–13.2) | Ref |
| -Yes | 1178 | 122 | 11.4 (7.4–17.2) | 1.24 (0.67–2.30) |
| Kerosene: | ||||
| -No | 1907 | 181 | 10.5 (7.4–14.5) | Ref |
| -Yes | 586 | 61 | 10.2 (6.0–16.7) | 0.97 (0.49–1.92) |
| Firewood: | ||||
| -No | 2175 | 229 | 10.5 (7.8–13.9) | Ref |
| -Yes | 318 | 13 | 7.1 (3.4–14.5) | 0.66 (0.28–1.54) |
| Electricity: | ||||
| -No | 1647 | 159 | 11.5 (7.9–16.4) | Ref |
| -Yes | 846 | 83 | 8.7 (5.6–13.2) | 0.73 (0.39–1.36) |
OR, odds ratio; ref, reference category; 95% CI, 95% confidence interval. aWeighted for sampling weights. bBy self-identification
Seroprevalence of SARS-CoV-2 according to contact history and clinical characteristics
| Participants (n = 2493) | Seropositive participants (n = 242) | Seroprevalencea % (95% CI) | OR (95% CI) | |
|---|---|---|---|---|
| COVID-19 diagnosis (n = 2493): | ||||
| -No | 2373 | 144 | 6.4 (4.7–8.8) | Ref |
| -Yes | 120 | 98 | 68.8 (43.5–86.3) | 32.0 (10.7–96.3) |
| COVID-19 hospitalization (n = 120): | ||||
| -No | 109 | 88 | 69.5 (50.8–83.4) | Ref |
| -Yes | 11 | 10 | 59.3 (43.7–73.3) | 0.6 (0.2–1.8) |
| Contact with confirmed cases (n = 2492): | ||||
| -No | 2196 | 135 | 7.4 (5.3–10.2) | Ref |
| -Yes (≥ 1 person) | 296 | 107 | 31.2 (20.2–44.8) | 5.7 (3.0–10.9) |
| Exposure site (n = 296): | ||||
| -At home | 197 | 82 | 42.1 (21.1–58.7) | 3.9 (1.1–13.2) |
| -Work/small gatherings/others | 99 | 25 | 15.8 (6.3–34.5) | Ref |
| Quarantine (n = 296): | ||||
| -No | 123 | 32 | 21.9 (10.9–39.1) | Ref |
| -Yes | 173 | 75 | 41.0 (24.9–59.3) | 2.5 (0.9–7.3) |
| Any symptom:b | ||||
| -No | 1841 | 89 | 5.2 (3.5–7.7) | Ref |
| -Yes | 652 | 153 | 23.6 (17.1–31.6) | 5.6 (3.03–9.4) |
| Number of symptoms: | ||||
| -None | 1841 | 89 | 5.2 (3.5–7.7) | Ref |
| -1–2 symptoms | 275 | 32 | 19.1 (9.8–33.9) | 4.3 (1.8–10.0) |
| -2–3 symptoms | 195 | 46 | 19.6 (11.5–31.2) | 4.4 (2.1–9.2) |
| -≥ 5 symptoms | 182 | 75 | 38.1 (24.6–53.8) | 11.2 (5.6–22.3) |
| Seek medical care (n = 651): | ||||
| -No | 399 | 64 | 17.7 (11.5–26.1) | Ref |
| -Yes | 252 | 89 | 32.2 (21.5–45.1) | 2.21 (1.1–4.4) |
Chile 2020
OR, odds ratio; ref, reference category; 95% CI, 95% confidence interval. aWeighted for sampling weights. bCOVID-19 compatible symptoms including fever, cough, odynophagia, dyspnea, headache, myalgia, chest pain, abdominal pain, diarrhea, fatigue, anosmia and dysgeusia
Frequency and type of symptoms and presence of SARS-CoV-2 antibodies. Chile 2020
| Symptoms | Participants | Symptoms in seropositivea (%)* | Symptoms in seronegativea (%)* | OR (95% CI)b | ||
|---|---|---|---|---|---|---|
| Total (n = 2493) | Seropositive (n) | Seronegative (n) | ||||
| Fever | 173 | 65 | 108 | 24.9 | 4.8 | 6.6 (3.4–12.8) |
| Cough | 237 | 63 | 174 | 27 | 8.2 | 4.1 (2.0–8.8) |
| Odynophagia | 326 | 75 | 251 | 29.5 | 12.1 | 3.0 (1.7–5.4) |
| Dyspnea | 147 | 49 | 98 | 15 | 4.6 | 3.7 (1.8–7.4) |
| Headache | 434 | 113 | 321 | 45.9 | 15.9 | 4.5 (2.5–8.2) |
| Myalgia | 306 | 94 | 212 | 39.4 | 10.7 | 5.4 (3.1–9.5) |
| Chest pain | 108 | 45 | 63 | 22.2 | 3.2 | 8.8 (3.4–22.9) |
| Abdominal pain/diarrhea | 168 | 50 | 118 | 19.2 | 7.5 | 3.0 (1.3–6.5) |
| Fatigue/prostration | 181 | 61 | 120 | 24.9 | 5.5 | 5.7 (3.0–10.9) |
| Anosmia | 100 | 74 | 26 | 23.3 | 1.0 | 30.0 (12.1–74.6) |
| Dysgeusia | 89 | 66 | 23 | 21.6 | 0.8 | 32.9 (11.6–93.9) |
OR, odds ratio; 95% CI, 95% confidence interval. aWeighted for sampling weights. bReference category = seronegative
Estimation of SARS-CoV-2 infection fatality ratio from seroprevalence, Chile 2020
| Registered deaths 7 years and older | Population 7 years and older | Seroprevalence% (95% CI) | Estimate number of infected cases | Infection Fatality Ratio | ||
|---|---|---|---|---|---|---|
| % | 95% CIc | |||||
| Coquimbo-La Serena | – | 459,950 | 5.61 (3.3–9.5) | 25,803 | – | – |
| COVID-19 confirmed deathsa | 152 | – | – | – | 0.59 | (0.50–0.69) |
| COVID-19 attributed deathsb | 218 | – | – | – | 0.84 | (0.74–0.96) |
| Santiago | – | 6,382,709 | 11.03 (8.2–14.7) | 704,013 | – | – |
| COVID-19 confirmed deathsa | 9279 | – | – | – | 1.32 | (1.29–1.35) |
| COVID-19 attributed deathsb | 11,922 | – | – | – | 1.69 | (1.66–1.72) |
| Talca | – | 217,147 | 2.00 (0.8–4.7) | 4343 | – | . |
| COVID-19 confirmed deathsa | 112 | – | – | – | 2.58 | (2.15–3.09) |
| COVID-19 attributed deathsb | 132 | – | – | – | 3.04 | (2.57–3.59) |
| Overall | – | 7,059,806 | 10.40 (7.8–13.7) | 734,159 | – | – |
| COVID-19 confirmed deathsa | 9543 | – | – | – | 1.30 | (1.27–1.32) |
| COVID-19 attributed deathsb | 12,272 | – | – | – | 1.67 | (1.64–1.70) |
95% CI, 95% confidence interval. aInternational Classification of diseases (ICD-10) U07.1. bICD-10 U07.1 and U07.2. cWilson score
SARS-CoV-2 seroprevalence by dwelling and secondary attack rate
| Dwellings | Dwellings with seropositive residents | Residentsa | Seropositive residents | 2nd attack ratec | |||
|---|---|---|---|---|---|---|---|
| n | % (95%CI) | n | n | Attack rate%b (95% CI) | % (95% CI) | ||
| Coquimbo-La Serena | 219 | 16 | 7.3% (4.2–11.5) | 46 | 30 | 65.2% (49.8–78.6) | 46.7% (28.3–65.7) |
| Santiago | 675 | 123 | 18.2% (15.4–21.3) | 317 | 200 | 63.1% (57.5–68.4) | 39.7% (32.7- 46.9) |
| Talca | 261 | 9 | 3.5% (1.6–6.4) | 30 | 12 | 40.0% (22.7–59.4) | 14.3% (3.0–36.3) |
| Total | 1155 | 148 | 12.8% (10.9–14.9) | 393 | 242 | 61.6% (56.6–66.4) | 38.4% (32.2–44.8) |
Chile 2020
95% CI, 95% confidence interval. ano of people in dwellings with a seropositive member. b(seropositive residents/total residents). c(seropositive residents less 1 seropositive per dwelling)/(total residents less 1 seropositive per dwelling)
Social variables according to SARS-CoV-2 antibodies results by census zone
| Seropositive | Seronegative | ||
|---|---|---|---|
| % Individuals without access to tap water | 1.5%/0.02 | 1.6%/0.01 | 0.865 |
| % Dwellings with more than one household | 2.1%/0.2 | 1.9%/0.07 | 0.394 |
| % Dwellings with overcrowdinga | 7.6%/0.6 | 6.7%/0.3 | 0.202 |
| % Individuals without university education | 76.4%/2.9 | 64.5%/1.6 | 0.005 |
| % Migrant population | 7.3%/1.0 | 9.5%/0.6 | 0.17 |
| % Unemployed population | 6.8%/0.2 | 6.4%/0.1 | 0.149 |
| % Males | 48.1%/0.2 | 48.0%/0.09 | 0.648 |
| Population densityb | 3.1/6.4 | 2.8/3.9 | 0.004 |
Chile 2020
SD, standard deviation. aOvercrowding ≥ 2.5 people/bedroom bPopulation density = people/dwellings
Multivariate model of individual and ecological risk factors associated with SARS-CoV-2 antibodies
| Category | Multivariable ORa | 95% CI | |
|---|---|---|---|
| City: | |||
| -Talca | Ref | – | – |
| -Coquimbo-La Serena | 2.6 | 0.9–7.4 | 0.0795 |
| -Santiago | 4.8 | 1.9–12.6 | 0.0013 |
| Contact with a confirmed case: | |||
| -No | Ref | – | – |
| -Yes | 4.2 | 2.1–8.2 | < 0.0001 |
| Foreign: | |||
| -No | Ref | – | – |
| -Yes | 4.7 | 1.8–12.7 | 0.0020 |
| Sex: | |||
| -Female | Ref | – | – |
| -Male | 1.5 | 0.9–2.5 | 0.0966 |
| Age: | |||
| -7–14 | Ref | – | – |
| -15–24 | 0.9 | 0.4–2.3 | 0.8967 |
| -25–39 | 1.1 | 0.5–2.5 | 0.7904 |
| -40–59 | 1.1 | 0.5–2.3 | 0.7720 |
| -60 and more | 1.0 | 0.4–2.7 | 0.9858 |
| People without university education (%)b | 4.0 | 1.2–14.1 | 0.0296 |
| Population densityb | 1.8 | 1.0–3.0 | 0.0387 |
OR, odds ratio; 95% CI, 95% confidence interval. aWeighted for sampling weights. bPer census zone
Fig. 3Empirical Bayesian Kriging predicted values for SARS-CoV-2 individual risk of infection for Santiago, Chile 2020
Fig. 4Empirical Bayesian Kriging, predicted values for SARS-CoV-2 individual risk of infection for La Serena-Coquimbo, Chile. 2020
Fig. 5Empirical Bayesian Kriging, predicted values for SARS-CoV-2 individual risk of infection for Talca, Chile 2020
Fig. 6Correlation between incidence of COVID-19 confirmed cases and seroprevalence rate from Empirical Bayesian Kriging model. Chile 2020